Kymera CEO exercises options and sells 30,000 shares

Kymera Therapeutics, Inc. director and CEO Nello Mainolfi reported an exercise-and-sell transaction in Kymera common stock.

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. director and CEO Nello Mainolfi reported an exercise-and-sell transaction in Kymera common stock. On April 29, 2026, he exercised stock options to acquire 30,000 shares at $2.08 per share and then sold 30,000 shares of common stock in open-market trades.

The sales were split into blocks of 936, 12,059, and 17,005 shares at weighted average prices of about $82.45, $81.70, and $80.74. According to the filing, these trades were executed under a pre-arranged Rule 10b5-1 trading plan. After the transactions, Mainolfi directly held 666,195 shares of Kymera common stock.

Insider Trade Summary 10b5-1

Exercise and Sale: 30,000 shares ($2.37M approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Mainolfi Nello

Role Chief Executive Officer

Sold 30,000 shs ($2.44M)

Approx. gross sale proceeds $2.44M

Approx. exercise cost $62K

Approx. pre-tax spread $2.37M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	30,000	$0.00	$0.00
Exercise	Common Stock	30,000	$2.08	$62K
Sale	Common Stock	17,005	$80.74	$1.37M
Sale	Common Stock	12,059	$81.70	$985K
Sale	Common Stock	936	$82.45	$77K

Holdings After Transaction: Stock Option (Right to Buy) — 215,559 contracts (Direct); Common Stock — 666,195 shares (Direct)

Footnotes (5)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.23 to $81.215, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.23 to $82.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.30 to $83.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. F5. The shares underlying this stock option are fully vested and exercisable.

Key Figures

Shares sold: 30,000 shares Option exercise size: 30,000 shares Exercise price: $2.08/share +5 more

8 metrics

Shares sold 30,000 shares Total Kymera common shares sold on April 29, 2026

Option exercise size 30,000 shares Stock options exercised into Kymera common stock on April 29, 2026

Exercise price $2.08/share Strike price of stock options exercised by CEO

Sale price block 1 $82.45/share Weighted average price for 936 shares of Kymera common stock sold

Sale price block 2 $81.70/share Weighted average price for 12,059 shares of Kymera common stock sold

Sale price block 3 $80.74/share Weighted average price for 17,005 shares of Kymera common stock sold

Post-transaction holdings 666,195 shares Kymera common shares directly held by CEO after transactions

Option expiration November 13, 2029 Expiration date of the stock option exercised

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), derivative security, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kymera Therapeutics (KYMR) report for Nello Mainolfi?

Kymera Therapeutics reported that CEO Nello Mainolfi exercised options for 30,000 shares at $2.08 and sold 30,000 common shares in open-market trades. The filing shows this as an exercise-and-sell pattern rather than a pure purchase or sale.

How many Kymera (KYMR) shares did CEO Nello Mainolfi sell and at what prices?

Nello Mainolfi sold a total of 30,000 Kymera common shares in three blocks of 936, 12,059, and 17,005 shares. The weighted average sale prices were approximately $82.45, $81.70, and $80.74 per share, according to the Form 4 disclosure.

Did Kymera’s CEO use a Rule 10b5-1 trading plan for these KYMR share sales?

Yes. The Form 4 states that Nello Mainolfi’s Kymera share sales on April 29, 2026 were executed under a Rule 10b5-1 trading plan dated September 6, 2024. Such plans pre-schedule trades, making the timing more routine and less discretionary.

What is the option exercise disclosed for Kymera (KYMR) CEO Nello Mainolfi?

The filing shows Mainolfi exercised stock options covering 30,000 Kymera common shares at an exercise price of $2.08 per share. These options were fully vested and exercisable, and the exercise coincided with same-day sales of an equal number of common shares.

How many Kymera (KYMR) shares does Nello Mainolfi hold after this Form 4 transaction?

After the reported transactions, Nello Mainolfi directly held 666,195 shares of Kymera common stock. This figure reflects his direct ownership position as stated in the Form 4 following the April 29, 2026 option exercise and share sales.

Were Kymera (KYMR) CEO Nello Mainolfi’s reported sale prices single trades or averages?

The reported sale prices are weighted averages. Footnotes explain that the Kymera shares were sold in multiple trades within price ranges, for example $80.23 to $81.215, and that detailed price breakdowns are available on request from relevant parties.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/29/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mainolfi Nello

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/29/2026		M(1)		30,000	A	$2.08	696,195	D
Common Stock	04/29/2026		S(1)		17,005	D	$80.74(2)	679,190	D
Common Stock	04/29/2026		S(1)		12,059	D	$81.7(3)	667,131	D
Common Stock	04/29/2026		S(1)		936	D	$82.45(4)	666,195	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.08	04/29/2026		M(1)			30,000	(5)	11/13/2029	Common Stock	30,000	$0	215,559	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.23 to $81.215, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.23 to $82.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.30 to $83.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The shares underlying this stock option are fully vested and exercisable.

	/s/ Bruce Jacobs, as Attorney-in-Fact	04/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)